Related Experiment Video
Updated: Jun 18, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Apixaban: an emerging oral factor Xa inhibitor
Christopher Roser-Jones1, Richard C Becker
1Department of Medicine, Duke University Medical Center, Duke University School of Medicine, Durham, NC, USA.
Journal of Thrombosis and Thrombolysis
|November 19, 2009
Summary
Apixaban, a direct factor Xa inhibitor, shows promise in preventing and treating thromboembolic diseases. While demonstrating reduced bleeding risk, its efficacy for VTE events requires further investigation in ongoing clinical trials.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Hematology
Background:
- Apixaban is an oral direct factor Xa inhibitor.
- It is in late-stage clinical development for thromboembolic diseases.
- Current treatments for venous thromboembolism (VTE) prophylaxis have established standards.
Purpose of the Study:
- To evaluate the efficacy and safety of apixaban in various thromboembolic conditions.
- To compare apixaban with existing treatments and placebo.
- To assess apixaban's role in VTE prophylaxis, secondary treatment, and post-acute coronary syndrome management.
Main Methods:
- Phase II and III clinical trials are investigating apixaban.
- Studies include comparisons with placebo and current treatment standards.
- Participants include patients with VTE, acute coronary syndrome, and non-valvular atrial fibrillation.
Main Results:
- Apixaban demonstrated decreased rates of clinically significant bleeding compared to VTE prophylaxis standards.
- Results regarding non-inferiority for VTE events are mixed.
- The APPRAISE-1 trial showed increased bleeding risk and a trend toward decreased ischemic events post-acute coronary syndrome.
Conclusions:
- Apixaban shows potential in managing thromboembolic diseases, particularly with a favorable bleeding profile.
- Further research is ongoing to confirm its non-inferiority for VTE events.
- Ongoing phase III trials will clarify its role in acute coronary syndrome and atrial fibrillation management.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...